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PATENTABLE SUBJECT MATTER REQUIREMENTS:
AN EVALUATION OF PROPOSED EXCLUSIONS TO INDIA'S PATENT
LAW IN LIGHT OF INDIA'S OBLIGATIONS UNDER THE TRIPS
AGREEMENT AND OPTIONS FOR INDIA
Rajnish Kumar Rai6
Abstract
In April 2005, the Technical Expert Group (the Expert Group) on patent law issues, headed
by Dr. RA Mashelkar, considered the TRIPS Agreement's consistency of (a) limiting the
grant of patents for pharmaceutical substances to new chemical entities or to new medical
entities, and (b) excluding micro-organisms from patent eligibility.
In December 2006, the Expert Group submitted its report. The report indicated that (a)
limiting the grant of patents for pharmaceutical substances to new chemical entities or to new
medical entities, and (b) excluding micro-organisms from patent eligibility would be in
contravention with India's obligation under the TRIPS Agreement. However, certain
stakeholders criticized the report because the Expert Group took up the question of what is in
India's national interest, instead of examining whether restricting patents in pharmaceuticals
to new chemical entities and excluding micro-organism would violate TRIPS. The Expert
Group later withdrew its report due to "technical inaccuracy and plagiarism." However, in the
midst of this controversy, the main issue regarding the legality of limiting these grants and
excluding eligibility was completely lost.
Through examination of the TRIPS Agreement in conjunction with the interpretation of other
international treaties/conventions, this article presents evidence that neither of these two per
se exceptions to patentable subject matter (i.e., the availability of patents) is consistent with
the obligations of India under the TRIPS Agreement. This article also proposes legal options
available to India to safe-guard its national interests.
The author is a senior police officer of the Indian Police Service, an elite constituent of the Indian Civil
Services. The author is extremely grateful to Professor A. Damodaran and Professor Rupa Chanda for their
guidance and suggestions in writing this article. In addition, the author is grateful to Professor Gopal Naik
for his relentless encouragement. However, the author alone is responsible for any deficiencies.
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INTRODUCTION
In March 2005, the Indian government introduced the 2005 Patent (Amendment) Bill
in the Parliament to fulfill India's international obligations under the Agreement on Trade-
Related Intellectual Property Rights (TRIPS Agreement or TRIPS).' India's compliance with
the TRIPS Agreement has been a very long and circuitous journey. The journey began with
the 2003 Patent (Amendment) Bill under the National Democratic Alliance (NDA)
Government led by the Bhartiya Janata Party (BJP), but the Bill soon lapsed due to a change
in government at the centre and the consequent dissolution of the House of People. 2 The new
Congress led United Progressive Alliance (UPA) government endorsed the Bill, but because
of pressure from the Left Parties, the UPA was unsure of whether the Bill would go through
Parliament before the TRIPS Agreement deadline of January 1, 2005.' Hence, the UPA
passed the Bill as a presidential ordinance in order to meet the above deadline.' Under
pressure from the Left parties, the UPA immediately made changes to the Ordinance and then
introduced the Bill in the Parliament. However, the Left Parties were not completely
satisfied. In both Houses of the Parliament, the controversy regarding patentability of micro-
organisms remained. In addition, both Houses bitterly debated whether the definition of
'pharmaceutical substance' meant a "new chemical entity (NCE)" or a "new medical entity
(NME).' '6 Even though Parliament had not resolved these issues, rather than risk any further
delays, the government did what it does best when it is caught in a spot-appoint a
committee. Mr. Kamal Nath, the Minister for Commerce and Industry, strategically assured
the Parliament that he would refer the contentious issues to an expert committee for a detailed
Agreement on Trade Related Intellectual Property Rights, Apr. 15, 1994, Marrakesh Agreement
Establishing the World Trade Organization, Annex IC. 33 I.L.M. 1125 (1994) [hereinafter TRIPS
Agreement], available at http://www.wto.org/english/docs e/legal e/27-trips.pdf.
2 Shamnad Basheer, India's Tryst with TRIPS: The Patents (Amendment) Act 2005, 1 INDIAN J.L. & TECH. 15
(2005).
See TRIPS Agreement, supra note, art. 65.4 (permitting developing country member who did not grant
pharmaceutical product patents prior to the TRIPS Agreement to harmonize its national legislation on
intellectual property rights with the international TRIPS obligations by Jan. 1, 2005).
4 See Basheer, supra note 2.
5 See Basheer, supra note 2.
6 See Report of the Technical expert panel on Patent Law Issues (Dec. 2006) [hereinafter Report], available at
http://www.patentoffice.nic.in/ipr/patent/mashelkar committee report.doc.
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examination. The government made this deft move to prevent any further stalling of the
passage of the Indian Patent Act by the Left Parties. Parliament finally passed the Bill in the
third week of March as the Patent (Amendment) Act, 2005.1
Under this backdrop, the Indian government, Ministry of Commerce and Industry, and
Department of Industrial Policy and Promotion established the Technical Expert Group (the
Expert Group) on patent law issues headed by Dr. RA Mashelkar'
The government assigned the Expert Group with the task of examining whether the
enactment of two proposed changes to India's patent law would be consistent with India's
obligations under the TRIPS Agreement. The government gave the Expert Group two issues
to examine:
(a) whether it would be compatible with TRIPS to limit the grant of patents for
pharmaceutical substance to new chemical entities or to new medical entities involving one or
more inventive steps; and,
(b) whether it would be compatible with TRIPS to exclude micro-organisms from
patenting9
In December 2006, the Expert Group submitted its report to the government and
opined that 1) limiting the grant of patents for pharmaceutical substance to only new
chemical entities was not compliant with TRIPS', and 2) excluding micro-organisms from
patent protection would be violate TRIPS."
A group of critics and stakeholders severely criticized the Expert Group's
recommendations by alleging that the group had based its recommendations on irrational or
highly contestable assumptions without sufficient evidence in the report to support its
7 See Basheer, supra note 2.
8 See Press Release, Government of India Press Information Bureau, Kamal Nath Constitutes Technical
Expert Group on Patent Law Issues (Apr. 6, 2005) available at http://commerce.nic.in/Apr05_release.htm.
The 5-member Technical Expert Group on patent law issues was constituted by Mr. Kamal Nath, Union
Minister for Commerce & Industry, Govt. of India in Apr. 2005.
See id. (emphasis in original;), also O.M. No. 12/14/2005-IPR-III. Apr. 5, 2005 of Government of India,
Ministry of Commerce & Industry. Department of Industrial Policy & Promotion (conveying the terms of
reference to the Technical Expert Group technical expert panel on patent law issues.) (on file with author).
10 See Report, supra note 6.
11 Id.
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interpretation. For instance, according to the Secretary General of Indian Pharmaceutical
Alliance, D.G. Shah, "as the title suggests, the reference to the group was on 'patent law,' but
there is hardly any evidence in the report to support its interpretation. Most parts of the report
are devoted to narrating the positions of various interest groups, but very little is devoted to
what made the Technical Group take the view that to limit patentability to NCEs is not
compatible with the TRIPS Agreement."'2 K.M. Gopakumar of CENTAD, an NGO that deals
with international trade policies, was more critical in his response. He stated, "[t]he terms of
reference clearly mention that the task was to find whether it would be TRIPS compatible to
limit the grant of patent for a pharmaceutical substance to a new chemical entity or to a new
medical entity involving one or more inventive steps. However, the committee does not
answer this question and also cites so-called national interest to make its recommendation."' 3
The report later attracted huge controversy when many found that the Expert Group
took its conclusion verbatim from an article authored by Shamnad Basheer for the UK's
Intellectual Property Institute. 14 Basheer's article was submitted to the Mashelkar Committee
during its consultation process. However, in an annexure to the report, the Expert Group not
only included submissions of the work of Shamnad Basheer, but also all other submissions
made during the consultation process. 15 The Expert Group later withdrew its report because of
"technical inaccuracy and plagiarism". The allegation of plagiarism further reinforced the
public health activists' claim that the Mashelkar Committee toed the line of multinational
pharmaceutical industry by recommending that India needed to strengthen the patent law
further than it did in 2005 to meet its obligations under the TRIPS Agreement."
However, in the midst of this controversy, the main issue regarding the legality of
limiting these grants and excluding eligibility was completely lost. Unfortunately, the debate
Joe C Mathew, Mashelkar's View on Wider Patentability Flayed, REDIFF NEWS, Jan. 16, 2007,
http://in.rediff.com/money/2007/jan/ 6patent.htm.
13 Id.
14 Shamnad Basheer, Limiting the Patentability of Pharmaceutical Inventions and Micro-organism: A TRIP
Compatibility Review, Intellectual Property Institute (2005). available at
http://www.altlawforum.org/ADVOCACY CAMPAIGNS/mashelkar/I P I %20Report%20on % 2 01ndia%20P
atent% 2 0Act%202006.pdf.
15 See Report, supra note 6.
1, Manoj Mitta, Mashelkar Takes Back Report After Plagiarism Row, THE TIMES OF INDIA, Feb. 22, 2007,
available at http://timesofindia.indiatimes.com/articleshow/1653926.cms.
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on the issue was very superficial and did not delve into the details of the legal nuances in the
provisions of the TRIPS Agreement. In addition to criticizing the Mashelkar' Committee
Report, some activists even questioned the academic integrity of Shamnad Basheer. Many
alleged that since Interpat funded the UK's Intellectual Property Institute, Basheer's article
did not reflect any independent judgment, but merely reiterated Interpat's industry position.'
In the current context, the Expert Group's report has not been well received by some
of the stakeholders. Serious doubts have been raised about Basheer's work on purely
academic grounds. More importantly, the key issue regarding the legal evidence to support
the Expert Group Report's recommendations has been drowned out by the plagiarism
controversy. In this context of negative polemic, this paper attempts to reexamine the issue
from a purely legal perspective, and evaluate the proposed exclusions in terms of India's
obligations under the TRIPS Agreement.
This article is divided into three parts. Part one provides a general overview of the
fundamentals of patent systems, including the nature and purpose of patent rights, and the
requirements for patentability. This discussion reveals that per se exclusions from
patentability based solely on the subject matter of the invention are generally incompatible
with patent eligibility analyses. Part two discusses the legal obligations of India under the
TRIPS Agreement with respect to eligibility for patent protection. This section interprets
these provisions as would a WTO Dispute Settlement Panel or the Appellate Body. This
section also discusses how India's patent law would violate the TRIPS Agreement if
Parliament makes the proposed amendments. This section also examines why the various
exceptions in the TRIPS Agreement would not shelter India's proposed amendments from a
TRIPS violation. Part three discusses India's national interest, specifically the options that the
flexibilities in the TRIPS Agreement provide to India on a national level. The final part also
examines the needs of the local pharmaceutical industry with respect to its standing and
reputation in the WTO as a safe trading partner. This article concludes that India cannot
accept the proposed exclusions without derogating its international obligations under the
TRIPS Agreement and that the Expert Group's recommendations were legally in line with
India's obligation under the TRIPS Agreement.
17 C. Park & A. Prabhala, Patent Wrong., TF\vWS OF INDIA, Feb. 12, 2007, available at
http://timesofindia.indiatimes.com/articleshow/1593525.cms.
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I. INTRODUCTION TO PATENT SYSTEM CONCEPTS
A basic understanding of patent systems reveals that per se exclusions of patentability
based strictly on the invention's subject matter are usually contrary to the fundamental
principles and motivations of patent protection. Patent systems encourage innovation by
making the development of inventions into new products and services commercially
feasible." Ultimately, patent systems benefit society and consumers by delivering new
products and services based on technological innovation.20  Patents facilitate the
commercialization process by enabling innovators to appropriate from their investments by
preventing, for a limited period, the unauthorized copying of the patented invention by
competitors. 2' By doing so, the innovator can secure a commercially viable return on his or
her investments in developing the invention into a new product or service.22 Moreover, patent
systems require clear and complete disclosures of the inventions in the text of the published
patents.23 Therefore, patent systems encourage the diffusion of knowledge for the benefit of
society unlike an alternative system dependent on trade secrets. 4
The proposed amendments to India's patent law exclude certain categories of subject
matter from eligibility for patent protection. Consequently, excluding per se certain
categories of subject matter from eligibility for patent protection, as the amendments to
India's patent law propose, would (1) reduce the incentives for innovation with respect to that
subject matter; (2) reduce the availability of new products and services connected with that
See e.g., 35 U.S.C. § 101 (the United States Supreme Court has repeatedly and consistently stated that there
are only three categories of subject matter for which one may not obtain patent protection: (1) laws of
nature; (2) natural phenomena; and (3) abstract ideas).
19 Commission on Intellectual Property Rights (CIPR), Integrating Intellectual Property Rights and
Development Policy [hereinafter CIPR], available at
http://www.iprcommission.org/papers/pdfs/final report/CIPRfullfinal.pdf.
20 David Encaoua, Dominique Gullec & Catalina Martinez, Patent systems for encouraging innovation:
Lessons from economic analysis (Feb. 2005), available at http://eurequa.univ-
paris I .fr/membres/encaoua/pdf The%/ 20ECONOMICS%/ 200F%/ 20PATENTS%/ 20june%/o202005.pdf.
21 Id.
22 Id.
23 See e.g., 35 U.S.C. § 112.
24 Gaurav Wahie, Evaluating Trade Secrets Under The IPR Paradigm: The Hypothesis Of Trade Secrets As A
Right Analysed In The Pure Hohfeldian Sense, available at
http://www.legalservicesindia.com/articles/tradesecrets.htm.
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subject matter; and (3) limit the diffusion of knowledge of new discoveries. As detailed
below, while Article 27 of the TRIPS Agreement provides discretion to WTO Members to
exclude a small set of subject matter from patentability, India's proposed exclusions do not
fall into this set.25
A. Overview of common standards for patentability
Patent systems impose a number of conditions on those wishing to obtain a patent for
an invention. These conditions ensure that the government awards a patent only when
justified, and that the rights provided under the patent correspond with the contribution made
by the inventor. Most patent systems use three standards to determine if the government
should patent an invention: 1) novelty of the invention, 2) inventive steps and, 3) industrial
application.2 6. The TRIPS Agreement also reflects these standards.2 However, TRIPS does
not define what an "invention" is, but only specifies the requirements that an invention
should meet in order to be patentable.2 ' This ambiguity leaves Members considerable freedom
to determine what an invention is. In addition, Members may also exclude from patentability
any substance that exists in nature as being a mere discovery and not an invention.
Apart from the above three standards, there are other two requirements that should be
met for the inventions to be patentable: eligibility and adequate disclosure.
1. Novelty
Under the novelty standard, the invention must not be identically disclosed in the
"prior art" (i.e., the entirety of publicly accessible knowledge existing before the inventor
25 See TRIPS Agreement, supra note 1, art. 27. (providing that subject to the provisions of para. 2 and 3,
patents shall be available for any inventions, whether products or processes, in all fields of technology,
provided that they are new, involve an inventive step and are capable of industrial application and subject to
para 4 of art. 65, para 8 of art. 70 and para.3 of this art., patents shall be available and patent rights
enjoyable without discrimination as to the place of invention, the field of technology and whether products
are imported or locally produced).
26 See Justine Pila, Bound Futures: Patent Law and Modern Biotechnology, 9(2) B.U.J. Sci. & Tech. Law
326, 378 (2003).
27 See TRIPS Agreement, supra note 1, art. 27.1.
28 Id.
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filed the patent application).29 This requirement generally means that the information must not
have been available to the public prior to the original application date (the priority date)."
Under most systems, information contained in publicly accessible forms (e.g., printed
publications, patents, information disseminated without restriction and accessible through
routine effort) is included in the prior art." TRIPS Article 27.1 grants WTO Members the
authority to require a showing of novelty as a condition of granting a patent.32
Since a Member grants a patent when an inventor discloses something new, then if
literature available to the public discloses the invention, the applicant (the "inventor") can
disclose nothing new in return for the grant. In that case, the inventor is not entitled to a
patent. In addition, if the Member has already granted the inventor a patent, he or she may
revoke the patent.33 The disclosure may have taken place within the jurisdiction or elsewhere
in the world." Due to the nature of invention, the discovery of things already existing in
nature,(e.g., a new plant or mineral) is not an invention.
29 See, e.g., Convention on the Grant of European Patents art. 54 (2), Oct. 5, 1973, 1065 U.N.T.S. 255
[hereinafter EPC],. (providing that the prior art shall include "everything made available to the public by
means of a written or oral description, by use, or in any other way, before the date of filing of the European
patent application.").
30 European Patent Office (EPO) case law holds that the theoretical possibility of having access to information
renders it available to the public (case T 444/88), whatever the means by which the invention was made
accessible, and in the case of prior public use irrespective of whether particular reasons exist for
analyzing the product (cases G 1/92). The United States requires complete disclosure in a single publication
to destroy novelty, despite the fact that a skilled person may have been able to derive the invention without
effort from a combination of publications. (EDTR: In re preceding sentence: Is this actually the law? I
vaguely recall reading recent case law to the contrary. ) In addition, under U.S. law, oral disclosure of an
invention outside the United States does not destroy novelty. This relative concept of novelty has allowed
the patenting in the USA of knowledge and materials used by indigenous communities abroad. See, e.g.,
Carlos Correa, THE QUAKER UNITED NATIONS OFFICE (QUNO), GENEVA, Traditional Knowledge And
Intellectual Property: Issues And Options Surrounding The Protection Of Traditional Knowledge (2001),
available at
http://www.iucn.org/themes/pbia/themes/trade/training/TK%/o20and%/o20Intellectual /%2OProperty.pdf.
31 See e.g., 35 U.S.C. § 102.
32 See TRIPS Agreement, supra note 1, art. 27.1.
33 See e.g., 35 U.S.C. § 102(b).
34 See 35 U.S.C. § 102(a).
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2. Inventive step
This standard measures the degree of "inventiveness" of the invention relative to the
prior art. 5 An invention must involve an inventive step-meaning that the invention must not
have been obvious from the prior art to a person of ordinary skill in that particular field of
technology at the time the inventor filed the patent application.316 An invention that is "novel"
can still lack an inventive step, and therefore the Member will deny the patent.37 In other
words, the invention must not merely be something new; it must represent a development
over prior art.
Inventive step, like novelty, must be measured at the time the inventor files the patent
application, rather than after the inventor files the application and has gained additional
perspective and knowledge. 39The latter improperly employs hindsight to assess the merits of
the invention.40 TRIPS Article 27.1 grants WTO Members the authority to require a showing
of inventive step or non-obviousness as a condition of granting a patent.
In Europe and in many other countries this requirement is generally described as an
"inventive step," in the United States lawmakers define the requirement as "non-
35 See 35 U.S.C. § 103 (specifies that a patent may not be obtained if it contains only obvious differences from
prior art).
36 See 35 U.S.C. § 103(a). The obviousness inquiry is highly fact specific and not susceptible to per se rules.
For a patent to be non-obvious it must display "ingenuity beyond the compass" of a person of ordinary skill
in the art.
37 See TRIPS Agreement, supra note 1, art. 27.1(provides that "... patents shall be available for any
inventions, whether products or processes, in all fields of technology, provided that they are new, involve
an inventive step and are capable of industrial application.... Thus, even if the applicant can demonstrate
patentable subject matter, utility and novelty, the patent will not issue if the invention is trivial. In order to
determine if an invention is trivial it is necessary to see if there was motivation in the prior art to do what
the inventor has done. If the prior art does not explicitly, and with identity of elements, teach the invention,
the patent applicant may still be thwarted if there are a number of references that, when combined, would
produce the claimed invention.
38 European Patent Office (EPO) jurisprudence distinguishes "inventive step" from technical progress.
Therefore, technical progress comparisons with marketed products support for this requirement being
satisfied are not sufficient. An inventor must demonstrate the presence of an inventive step with regard to
the closest state of the art. See UNCTAD, PATENTS: SUBJECT MATTER AND PATENTABILITY
REQUIREMENTS, 360 (2004)[hereinafter UNCTAD], available at
http://www.iprsonline.org/unctadictsd/docs/RB2.5 Patents 2.5.1 update.pdf.
39 See UNCTAD supra note 38 at 360.
40 Id.
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obviousness".'
3. Industrial applicability
The invention must be capable of being used in any kind of industry (including
agriculture). Industry, in this sense, is any physical activity of a technical character.42
Members considerably differ in their treatment of industrial applicability. In the U.S.,
lawmakers apply the concept of "utility".43 Hence, an inventor can patent certain
developments that do not lead to an industrial product in the U.S.. An invention only needs to
be operable and capable of satisfying some function of benefit to humanity (i.e., useful).44
This concept is broader than the industrial applicability required in Europe and other
countries.15 The U.S. rule permits the patentability of purely experimental inventions that
cannot be made or used in an industry, or that do not produce a so-called technical effect.46
These less stringent requirements are illustrated by the fact that the U.S. government grants a
large number of patents on methods of doing business, and research tools, such as expression
sequence tags (ESTs) and single nucleotide polymorphisms (SNPs) 7 Surgical techniques and
diagnostic procedures could arguably fail this requirement, but can be specifically excluded
from patentability under Article 27.3 (a).48
41 See TRIPS Agreement, supra note 1, art. 27.1, n.5 (specifically permits a Member to consider -inventive
step" synonymous with "non-obvious").
42 The technical character of an invention is a basic requirement of patentability. See TRIPS Agreement, supra
note 1, art. 27.1 (". . . patents shall be available ... in all fields of technology .... " (emphasis added)). Also
See Guidelines for Examination in the European Patent Office [hereinafter EPO Guidelines] at Pt. C, Ch.
IV, § 5.1 (June 2005), (provides that "...'[i]ndustry' should be understood in its broad sense as including
any physical activity of 'technical character' i.e. an activity which belongs to the useful or practical arts as
distinct from the aesthetic arts.), available at http://www.european-patent-
•org/legal/gui lines/pdf 2005.
43 See TRIPS Agreement, supra note 1, art. 27.1. n.5 (specifically permits a Member to consider "capable of
industrial application" synonymous with "useful").
44 DONALD S. CHISUM & MICHAEL A. JACOBS, UNDERSTANDING INTELLECTUAL PROPERTY LAW 2:50 (1992).
45 See UNCTAD, supra note 38 at 361.
46 It should be noted that "technical effect" has no official definition. The doctrine has its origins in German
patent law. See GRAHAM DUTFIELD, INTELLECTUAL PROPERTY RIGHTS AND THE LIFE SCIENCE INDUSTRIES:
A TWENTIETH CENTURY HISTORY 81 (2003).
47 The guidelines for examining utility were changed in the U.S. in 2001, possibly leading to the exclusion
from patentability of some of these matters. See USPTO Utility Examination Guidelines 66 Fed. Reg. 1092
(Jan. 5, 2001).
48 See UNCTAD, supra note 38 at 361.
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4. Eligibility
The standards mentioned above identify which scientific and technological advances
are "inventions" and, further, which "inventions" can be patented. In addition to using a
general requirement for industrial applicability of the invention," some countries precisely
identify categories of subject matter that are not inventions, and which types of inventions the
government will not patent.50 Other countries define eligibility in broad terms, without per se
exclusions.5 The industrial application requirement of most countries is inclusive of virtually
any type of commercial or industrial enterprise. 52 TRIPS Agreement limits the authority of
WTO Members to define patent eligibility, and requires a showing of industrial application or
usefulness as a condition of granting a patent. 5'3Paragraphs two and three of TRIPS Article 27
provide discretion to Members to exclude certain limited categories of subject matter from
patentability, none of which encompass the exclusions in the proposed amendment to Indian
patent law.54 . Pharmaceutical products and micro-organisms do not figure on this list of
TRIPS' designated subject matter exclusions. We will take up this important matter again in
Section II.
5. Adequate disclosure
This standard requires an applicant to provide technical information about the
invention such that others are able to reproduce the full scope of what the inventor claims in
4 See, e.g., EPC, supra note 29, art. 57 ("[A]n invention shall be considered as susceptible of industrial
application if it can be made or used in any kind of industry, including agriculture.").
5o See, e.g., EPC, supra note 29, art. 52(2) (identifies discrete categories of subject matter that are not
inventions);i. d art. 52(4) (categorizes the inventions that are deemed to not possess an industrial
application and are thus ineligible to be patented);i. Id art. 53 (lists the inventions that are not to be
patented regardless of whether they meet the standards of industrial applicability, novelty and inventive
step).
51 See 35 U.S.C. § 101(The U.S. patent system defines "any new and useful process. machine, manufacture, or
composition of matter, or any new and useful improvement thereof' to be eligible to be patented.) The U.S.
Supreme Court found that Congress chose the expansive language of 35 U.S.C. § 101 so as to include
"anything under the sun that is made by man." Diamond v. Chakrabarty, 447 U.S. 303, 308-09 (1980). The
U.S. patent law nevertheless excludes from eligibility subject matter that is not a process, machine, article
of manufacture or composition of matter. See Id It also holds as unpatentable inventions that are not
"useful" meaning, inventions that are abstract ideas or not distinguishable from laws of nature. See Id.
52 See UNCTAD, supra note 38 at 361.
53 See TRIPS Agreement, supra note 1, art. 27.
54 See UNCTAD, supra note 38 at 356.
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his or her patent application." TRIPS Article 29.1 generally refers to the authority WTO
Members have to impose disclosure requirements.
These standards vary slightly in how different countries apply them.5 In principle,
however, nearly every country incorporates some form of these five functional requirements
in their patent system."
As noted above, the primary international authority defining the requirements of
patent systems is the TRIPS Agreement. The other major treatises that influence international
patent law standards are the Paris Convention for the Protection of Industrial Property (Paris
Convention,) 59 the Patent Cooperation Treaty (PCT,)"' and the Patent Law Treaty (PLT)f'
International patent law standards have evolved to reflect and apply these five basic standards
in varying ways, and to address needs of inventors to secure patents in different countries.62
55 See 35 U.S.C. § 112 (specifies that once the first four patentability requirements are satisfied the applicant
still must describe the invention with enough particularity such that those skilled in the art will be able to
make, use and understand the invention that was made by the inventor.
56 See TRIPS Agreement, supra note 1, art. 29.1 (providing that [m]embers shall require that an applicant for
a patent shall disclose the invention in a manner sufficiently clear and complete for the invention to be
carried out by a person skilled in the art and may require the applicant to indicate the best mode for carrying
out the invention known to the inventor at the filing date or, where priority is claimed, at the priority date of
the application.").
57 See UNCTAD, supra note 38 at 362.
58 Id.
59 Paris Convention for the Protection of Industrial Property, Mar. 20, 1883, 21 U.S.T. 1583, 828 U.N.T.S.
305 (as revised at Stockholm on July 14, 1967) [hereinafter Paris Convention].
60 Patent Cooperation Treaty, June 19. 1970, 28 U.S.T. 7645, 1160 U.N.T.S. 231[hereinafter PCT].
61 Patent Law Treaty, June 1. 2000, 39 I.L.M. 1047 [hereinafter PLT].
62 Patent rights are territorial in nature. This means that patents confer rights over acts done within the
territory of the country that issued the patent, with certain very limited exceptions (e.g., the right to prevent
importation of a product made by using a patented process outside of the territory of the country).
Moreover, patents issued by the countries of the Paris Union (including India) must be "independent" of
patents issued in other countries, even where they are part of the same patent family. See Paris Convention,
supra note 59, art. 4bis. The territorial nature of patents means that companies must pursue patents in each
country in which they desire to have rights. To facilitate the procurement of patents in multiple
jurisdictions, treaties provide a "right of priority" (See Paris Convention, supra note 59, art. 4), and
facilitate the formalities associated with filing patent applications (e.g., PCT, supra note 60 and PLT, supra
note 61).
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B. Nature of the Patent Rights
Patents provide what are termed "exclusive rights."16 3 The principled basis for these
exclusive rights has been established in international law, and defined more explicitly in the
TRIPS Agreement .4 International human rights' norms also recognize the importance of
protecting intellectual property rights, as evidenced by the Universal Declaration of Human
Rights (UDHR), and the International Covenant on Economic, Social and Cultural Rights
(ICESCR). 65
Article 28.1(a) of the TRIPS Agreement specifies that if a WTO Member issues a
patent, this patent must confer on their owners the exclusive right to prevent the unauthorized
making, using, selling, offering for sale, or importing of the patented invention. In addition,
Article 28.1(b) of the TRIPS Agreement requires that patents confer the right to prevent the
unauthorized use of a product that results from a patented process invention, including
importation of that product into the country where the process patent originated7
Patents enable their owners to prevent the unauthorized use of the patented
technology through legal interventions.61 Specifically, patent owners can prevent
unauthorized use of the patented technology by commencing an action in a court for
63 See CIPR, supra note 19 at 12.
64 See TRIPS Agreement, supra note 1, arts.3, 4, 7 & 8.
65 Universal Declaration of Human Rights, G.A. Res. 217A, at 71, U.N. GAOR, 3d Sess., Ist plen. mtg., U.N.
Doc A/810, art. 27(2) (Dec. 12, 1948) [hereinafter UDHR (].providing that "[e]veryone has the right to the
protection of the moral and material interests resulting from any scientific, literary, or artistic production of
which he is the author."); International Covenant on Economic, Social and Cultural Rights, G.A. res. 2200A
(XXI), 21 U.N.GAOR Supp. (No. 16) at 49, U.N. Doc. A/6316 art. 15.1(c) (1966), 993 U.N.T.S. 3, entered
into force Jan. 3, 1976 [hereinafter ICESCR (].providing that "[t]he State Parties to the present Covenant
recognize the right of everyone: ... [t]o benefit from the protection of the moral and material interests
resulting from any scientific, literary or artistic production of which he is the author."). At the same time,
these agreements recognize the right to enjoy and share in scientific advancement and its benefits. See
UDHR art. 27(1); ICESCR art. 15.1(b).
66 See TRIPS Agreement, supra note 1, art. 28.1(a) (provides that "where the subject matter of a patent is a
product, to prevent third parties not having the owner's consent from the acts of: making, using, offering for
sale, selling, or importing6 for these purposes that product.").
67 See TRIPS Agreement, supra note 1, art. 28.1(b) (provides that "where the subject matter of a patent is a
process. to prevent third parties not having the owner's consent from the act of using the process. and from
the acts of: using, offering for sale, selling, or importing for these purposes at least the product obtained
directly by that process.").
68 See CIPR, supra note 19 at 12.
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infringement.": If infringement is proven, the court generally issues an injunction prohibiting
the continued unauthorized use of the patented invention.7 Ultimately, this ability to enjoin
the unauthorized conduct gives effect to the patent right."1 Part III of the TRIPS Agreement
requires WTO Members to make available adequate and effective judicial and administrative
procedures for enforcing intellectual property rights, including several procedures that are of
particular importance to a viable patent right.72
Patent rights are generally defined by the claims of the patent. The patent claims
reflect what is "novel," what involves an inventive step and, what is industrially applicable.73
The patent claims thus reflect and limit the scope of the patent rights.74 The claims must avoid
encompassing subject matter that is disclosed in or obvious from the prior art, or they will be
subject to rejection or invalidity.7" A valid patent claim can neither encompass what is
literally described in or obvious from the prior art, nor it can include subject matter that is
beyond what the inventor has described and enabled in the patent disclosure.76
69 Eugene R. Quinin, Jr.. Patent Infringement Damages. The Source for Intellectual Property News &
Information, available at http://www.ipwatchdog.com/patent damages.html.
70 Id.
71 Id.
72 See TRIPS Agreement, supra note 1, arts.34, 44, 50 (providing, respectively, the right to shift the burden of
proving non-infringement to one suspected of infringing a process patent, permanent injunctive relief, and
preliminary injunctive relief).
73 Carlos Correa, Integrating Public Health Concerns into Patent Legislation in Developing Countries, The
South Centre (2000), available at http://www.southcentre.org/publications/publichealth/pubiichealth.pdf.
74 Id.
75 Id.
76 Most countries permit relief for patent infringement in situations where the infringing product does not
literally meet each requirement of the claim, but is otherwise an insubstantial variation of the patented
invention. In the United States, this relief is referred to as infringement through the doctrine of equivalents,
and is applied as an equitable remedy. See Warner-Jenkinson Co. v. Hilton-Davis Chem. Co., 520 U.S. 17
(1997); Graham v. John Deere Co.. 383 U.S. 1 (1966).
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II. The 'Proposed Exclusions' Violates India's Obligations under the TRIPS
Agreement
The subject of the Technical Experts Group implicates the minimum patent protection
standards established by the TRIPS Agreement.77 An understanding of the compatibility (or
lack thereof, in this situation) of these proposed measures with the TRIPS Agreement
requires an evaluation of the text of the proposed measure in light of the text of the relevant
provisions of the TRIPS Agreement. The current section is devoted to filling out this
analytical framework.
The Dispute Settlement Panels and the Appellate Body has interpreted the TRIPS
agreement pursuant to Articles 31 and 32 of the Vienna Convention on the Laws of Treaties.78
This article will therefore follow the same approach.
Article 31 (1) of the Vienna Convention on the Law of Treaties provides:
A treaty shall be interpreted in good faith in accordance with the ordinary
meaning to be given to the terms of the treaty in their context and in the light
of its object and purpose.79
To determine the ordinary meaning of a particular word, panels and the Appellate
Body have often relied on dictionary definitions." Moreover, pursuant to Article 31(3) of the
Vienna Convention, WTO panels have also taken into account "subsequent practice in the
application of the treaty" by its Members when interpreting the TRIPS Agreement." Thus,
The WTO provides the institutional and legal foundation for the multilateral trading system that came into
being on January 1, 1995. (See DING LU, GUANZHONG JAMES WEN, HUIZHONG ZHOU, CHINA'S ECONOMIC
GLOBALISATION THROUGH THE WTO 176 (Ashgate Publishing Ltd.) (2003).
7 Vienna Convention on the Law of Treaties, May 23, 1969, 1155 U.N.T.S. 331 [hereinafter Vienna
Convention].
See, e.g., Panel Report, Canada Patent Protection of Pharmaceutical Products, 7 7.13, WT/DS1 14/R
(Mar. 17, 2000) (adopted Apr. 7, 2000); Panel Report, United States Section 110(5) of the United States
Copyright Act, 7 6.43, WT/DS/160/R (June 15, 2000) (adopted July 27, 2000).
80 See, e.g., Panel Report, United States Section 110(5) of the United States Copyright Act, 7 6.108-1.110,
WT/DS160/R; Appellate Body Report. Canada Term of Patent Protection, 7 65, WT/DS170/AB/R (Sept.
18, 2000) (adopted Oct. 12, 2000); Appellate Body Report, United States Section 211 Omnibus
Appropriations Act of 1998, 137, 172, 187, 215, WT/DS176/AB/R (Jan. 2, 2002) (adopted Feb. 1, 2002).
81 See, e.g., Panel Report, United States Section 110(5) of the United States Copyright Act, 7 6.65,
WT/DS 160/R ("In our view, state practice as reflected in the national copyright laws of members before
and after 1948, 1967, and 1971. as well as of WTO Members before and after the date that the TRIPS
Agreement became applicable to them, confirms our conclusion about the minor exceptions doctrine.").
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the practice of WTO Members may also be helpful to an analysis of the meaning of the
TRIPS Agreement, and references to such practice are included throughout this article.
Finally, Article 32 of the Vienna Convention allows for supplementary means of
interpretation in limited circumstances, and states as follows:
Recourse may be had to supplementary means of interpretation, including the
preparatory work of the treaty and the circumstances of its conclusion, in
order to confirm the meaning resulting from the application of Article 31, or
to determine the meaning when the interpretation according to Article 3 1:
(a) Leaves the meaning ambiguous or obscure; or
(b) Leads to a result which is manifestly absurd or unreasonable. 2
Consequently, where helpful, this article refers to the negotiating history of the TRIPS
Agreement.
The significant questions raised by India's proposed amendments relative to the
TRIPS Agreement are addressed below.
A. Generalframework of the TRIPS Agreement
The Indian Parliament entered the TRIPS Agreement into force on January 1, 1995,
after the conclusion of the Uruguay Round of negotiations and the creation of the WTO.8 3 The
TRIPS Agreement builds on intellectual property standards found in several pre-existing
multilateral agreements including the Paris Convention;84 the Berne Convention for the
Protection of Literary and Artistic Works;8 5 the International Convention for the Protection of
82 See Vienna Convention, supra note 78, art. 32.
83 India became member of WTO on Jan. 1. 1995, See WTO member countries, available at
http://www.wto.org/English/thewto e/whatis e/tif e/org6 e.htm.
' See Paris Convention, supra note 59. The current obligations of the Paris Convention are defined by the
Stockholm Act of the Convention, July 14, 1967, 21 U.S.T. 1583, 828 U.N.T.S. 305.
8_5 See Paris Convention, supra note 59. (as applied by the Paris Act of the Convention of July 24, 1971).
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Performers, Producers of Phonograms and Broadcasting Organizations86  ("Rome
Convention"); and, the Treaty on Intellectual Property in Respect of Integrated Circuits."
The primary objective of the TRIPS Agreement is to provide "effective and adequate
protection of intellectual property rights""8 and thereby, "contribute to the promotion of
technological innovation and to the transfer and dissemination of technology."89 The TRIPS
Agreement accomplishes this objective by establishing, in Part II, minimum substantive
standards for the availability, scope, and use of intellectual property rights,90 which the
national law of each WTO Member must adopt. In Part III, the TRIPS Agreement establishes,
minimum standards for the enforcement of intellectual property rights. In Part V, TRIPS
provides dispute settlement procedures to resolve disagreements among WTO Members over
compliance with TRIPS obligations."' Part VI provides certain transitional arrangements,
including provisions allowing developing countries (i.e., Article 65) and underdeveloped
countries (i.e., Article 66) additional time to implement certain TRIPS obligations relative to
developed countries.2
Part I of the TRIPS Agreement sets forth general provisions and basic principles that
apply throughout the other parts of the Agreement, including the cornerstone requirements of
national treatment and most-favoured nation (MFN) treatment.13 Within Part I, Article
86 See International Convention for the Protection of Performers, Producers of Phonograms and Broadcasting
Organizations, Oct. 26, 1961, 496 U.N.T.S. 43.
87 Treaty on Intellectual Property in Respect of Integrated Circuits (adopted in Washington on May 26, 1989),
available at http://www.wipo.int/export/sites/www/treaties/en/ip/washington/pdf trtdocs-woO1 .pdf.
8 See TRIPS Agreement, supra note 1, Preamble.
89 See TRIPS Agreement, supra note 1, art. 7.
A See TRIPS Agreement, supra note 1, part I & II. The TRIPS Agreement attempts to balance the longer term
objective of providing incentives for future inventions and creations, and the shorter term objective of
allowing people to use existing inventions and creations. The Agreement requires Members to protect
copyrights, trademarks, geographical indications, industrial designs, patents. integrated circuits, and data
(including trade secrets and certain test data).
91 See TRIPS Agreement, supra note 1, part V.
92 With respect to underdeveloped countries, the Doha Declaration on the TRIPS Agreement and Public
Health extended the transition period, such that they "will not be obliged, with respect to pharmaceutical
products, to implement or apply Sections 5 and 7 of Part II of the TRIPS Agreement or to enforce rights
provided for under these Sections until 1 January 2016.. .' See Doha WTO Ministerial 2001: Ministerial
Declaration, WT/MIN (01)/DEC/2 (Nov. 20, 2001) [hereinafter Doha Declaration].
93 See TRIPS Agreement, supra note 1, part I.
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1.1requires Members to implement the standards in TRIPS into their national laws. It also
provides Members with the discretion to provide standards of protection that exceed the
minimum standards specified in the Agreement. 4 As such, the TRIPS Agreement, similar to
the Paris Convention, is a "minimum standards" agreement.95
Article 1.1 also provides that Members have discretion in how they implement the
obligations of the TRIPS Agreement." Specifically, it provides that "Members shall be free to
determine the appropriate method of implementing the provisions of this Agreement within
their own legal system and practice." "7This provision is designed to ensure that the standards
of the Agreement are implemented in a manner that is compatible and effective within the
national legal system of each WTO Member.98 However, this provision does not authorize a
WTO Member to disregard an obligation, or refuse to confer rights in a manner that meets the
substantive standards of the TRIPS Agreement.99
The obligation to implement the TRIPS standards into national law ensures that
intellectual property owners can actually obtain the legal rights specified in the Agreement. 100
94 See TRIPS Agreement, supra note 1, art. 1.1 ("Members shall give effect to the provisions of this
Agreement. Members may, but shall not be obliged to, implement in their law more extensive protection
than is required by this Agreement, provided that such protection does not contravene the provisions of this
Agreement. Members shall be free to determine the appropriate method of implementing the provisions of
this Agreement within their own legal system and practice.").
95 See Paris Convention, supra note 59, art. 19 ("It is understood that the countries of the Union reserve the
right to make separately between themselves special agreements for the protection of industrial property, in
so far as these agreements do not contravene the provisions of this Convention.").
96 See TRIPS Agreement, supra note 1, art. 1.1.
97 Id.
98 Id.
9 WTO Members are free to decide how they will choose to give effect to the TRIPS obligations (in terms of
their national legal systems and practices), as long as they comply with the provisions of the Agreement.
The manner, by which such implementation is done, however, is subject to review through the WTO
dispute settlement process. See e.g., Appellate Body Report, India Patent Protection for Pharmaceutical
andAgricultural Chemical Products, 66, WT/DS50/AB/R (Dec. 19, 1997) (adopted Jan. 16, 1998) ("But,
as in the case cited above before the Permanent Court of International Justice, in this case, the Panel was
not interpreting Indian law 'as such;' rather, the Panel was examining Indian law solely for the purpose of
determining whether India had met its obligations under the TRIPS Agreement. To say that the Panel
should have done otherwise would be to say that only India can assess whether Indian law is consistent with
India's obligations under the WTO Agreement. This, clearly, cannot be so.").
100 See TRIPS Agreement, supra note 1, Preamble (-Recognizing, to this end, the need for new rules and
disciplines concerning: ... the provision of adequate standards and principles concerning the availability,
scope and use of trade-related intellectual property rights; ... ").
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For example, if the national government does not grant an innovator a patent, that innovator
cannot realize any of the rights specified in the Agreement. In this respect, the TRIPS
Agreement's recognition that intellectual property rights have the attributes of personal
property, and that the rights being addressed in the Agreement are "private" rights rather than
rights between governments is very important. 10' The TRIPS Agreement also requires
Members to grant rights in a timely fashion. Article 62.2 requires that procedures that the
government establishes to grant a patent must not take so long as to result in an unwarranted
curtailment of the period of protection (e.g., at least 20 years from the filing date of the
application resulting in the patent). 10 2
Finally, through Article 2.1, the TRIPS agreement incorporates the substantive
provisions of the Paris Convention and imposes these provisions as WTO obligations on all
WTO Members.'0 3
B. The 'proposed exclusion' violate Article 27 of the TRIPS Agreement
Part II, Section 5 of the TRIPS Agreement, sets forth certain requirements for
applicants and the minimum substantive standards of protection that Members must provide
to patent holders. 04 For purposes of analyzing the two proposed amendments to India's patent
law, the critical TRIPS provision is Article 27, which defines (a) the subject matter that is
eligible for patent protection, and (b) the requirements for patentability of such eligible
subject matter.0 5
1. The scope ofpatent eligibility under Article 27.1 is undeniably broad
The proposal to exclude micro-organisms and certain pharmaceutical substances from
the scope of subject matter eligible for patent protection is inconsistent with the broad scope
1o See TRIPS Agreement, supra note 1, Preamble ("Recognizing that intellectual property rights are private
rights.").
102 See TRIPS Agreement, supra note 1, art. 62.2 (provides that "[w]here the acquisition of an intellectual
property right is subject to the right being granted or registered, Members shall ensure that the procedures
for grant or registration, subject to compliance with the substantive conditions for acquisition of the right,
permit the granting or registration of the right within a reasonable period of time so as to avoid unwarranted
curtailment of the period of protection.").
1o3 See TRIPS Agreement, supra note 1, art. 2.1 ("In respect of Parts II, III and IV of this Agreement, Members
shall comply with Articles 1 through 12, and Article 19, of the Paris Convention (1967).").
104 See TRIPS Agreement, supra note 1, part II.
"" See TRIPS Agreement, supra note 1, art. 27.
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of eligibility TRIPS Article 27.1 requires.'" The TRIPS Agreement requires WTO Members
to grant patents on "any inventions" "in all fields of technology" subject only to specifically
enumerated exceptions." 7 Indeed, Article 27.1 of the TRIPS Agreement addressed one of the
main omissions of the Paris Convention-namely, a definition of what inventions must be
eligible for patents."8 Therefore, this new standard creates additional obligations that were
not part of the Paris Convention-standards that apply to all WTO Members.
As the first sentence of Article 27.1 of the TRIPS Agreement provides: "[sJubject to
the provisions of paragraphs 2 and 3, patents shall be available for any inventions, whether
products or processes, in all fields of technology, provided that they are new, involve an
inventive step and are capable of industrial application.' 19
Article 27.1 also requires Members to make patents available for both products and
processes.'0 Thus, the ordinary meaning of Article 27.1 clearly indicates that unless an
10' See TRIPS Agreement, supra note 1, art. 27.1 (provides that -[s]ubject to the provisions of paragraphs 2
and 3, patents shall be available for any inventions, whether products or processes, in all fields of
technology, provided that they are new, involve an inventive step and are capable of industrial
application.").
'0 See TRIPS Agreement, supra note 1, art. 27.1 (provides that "... [s]ubject to paragraph 4 of Article 65,
paragraph 8 of Article 70 and paragraph 3 of this Article, patents shall be available and patent rights
enjoyable without discrimination as to the place of invention, the field of technology and whether products
are imported or locally produced.").
o See Paris Convention, supra note 59. Under the Paris Convention, countries were free to exclude areas from
patentability, as well as to provide special rules for certain types of inventions. In addition, they had
freedom to define the requirements for patentability. TRIPS Agreement has changed this situation. Article
27.1 includes a general obligation of patentability addressing in this manner one of the major concerns
raised by the pharmaceutical industry with respect to prevailing regimes prior to TRIPS Agreement. See
TRIPS Agreement, supra note 1, art 27.1. In addition, all discrimination between sectors (as well as on the
basis of the place of invention) has been banned See UNCTAD-ICTSD, RESOURCE BOOK ON TRIPS AND
DEVELOPMENT (Cambridge University Press) (2005). This Resource Book has been prepared under the
responsibility of the UNCTAD-ICTSD Project on Intellectual Property Rights and Sustainable
Development.
... Article 10 of the WIPO Patent Law Treaty draft of 1991 was the basis for Article 27.1 of the TRIPS
Agreement. See UNCTAD. supra note 38 at 354. The draft required that patents be available for inventions
in all fields of technology. subject to the usual patentability requirements: novelty, industrial applicability,
and possession of an inventive step. Id.
iJ Process patents can confer rights not only over the use of the process in question, but also over products
obtained directly by the process. See TRIPS Agreement, supra note 1. art. 28. 1(b) ("where the subject
matter of a patent is a process, [a patent shall confer on its owner the exclusive rights] to prevent third
parties not having the owner's consent from the act of using the process. and from the acts of: using,
offering for sale, selling, or importing for these purposes at least the product obtained directly by that
process") see also Paris Convention, supra note 59, art. 5quater ("When a product is imported into a
country of the Union where there exists a patent protecting a process of manufacture of the said product. the
patentee shall have all the rights, with regard to the imported product, that are accorded to him by the
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invention is specifically authorized to be excluded from patent eligibility pursuant to Articles
27.2 or 27.3, a WTO Member may not refuse to grant it a patent, provided the invention is
new, involves an inventive step and is industrially applicable."' The use of the phrases "any
inventions" and "all fields of technology" make this point in the clearest of terms." 2
In other words, the law of each WTO Member may not in a per se manner exclude
inventions from eligibility unless they fall within classes of inventions that are specifically
authorized to be excluded pursuant to Articles 27.2 and 27.3. For inventions not within these
excluded categories, a WTO Member may deny the grant of a patent only if the invention
fails to meet the patentability (as opposed to patent eligibility) requirements of the
Agreement. Thus, a WTO Member must apply the evaluation of whether an invention is new,
involves an inventive step, and is capable of industrial application in the same manner and
with the same legal effect for pharmaceuticals or micro-organisms as the member does for all
other classes of technology.
2. Article 27.1 prohibits "discrimination" as to "the field of technology" of the invention
Paragraph I of Article 27 also establishes the principle of non-discrimination based on
the field of technology. It specifies that WTO Members may not refuse patents for inventions
in a particular technological field simply because the invention falls within that technological
field (subject to several exceptions that are inapplicable to India and the proposed
amendments )."3 Specifically, the second sentence of Article 27.1 provides, in pertinent part
that "patents shall be available and patent rights enjoyable without discrimination as to the
place of invention, the field of technology..."' The prohibition against discrimination,
legislation of the country of importation, on the basis of the process patent, with respect to products
manufactured in that country.").
. See TRIPS Agreement, supra note 1, art. 27.1.
112 Id.
113 See TRIPS Agreement, supra note 1, art. 27.2 (provides that [m]embers may exclude from patentability
inventions, the prevention within their territory of the commercial exploitation of which is necessary to
protect ordre public or morality, including to protect human, animal or plant life or health or to avoid
serious prejudice to the environment, ... "); see also TRIPS Agreement. supra note 1, art. 27.3 (provides
that "[m]embers may also exclude from patentability: (a) diagnostic, therapeutic and surgical methods for
the treatment of humans or animals; (b) plants and animals other than micro-organisms. and essentially
biological processes for the production of plants or animals other than non-biological and microbiological
processes ...
114 See TRIPS Agreement, supra note 1, art. 27.1.
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among other things, means that a WTO member may not deny a patent for inventions in one
technology sector that meet the requirements of the national law for novelty, inventive step
and industrial application (as they are used to measure patentability for inventions in other
technological fields).
The WTO Dispute Settlement Panel in Canada Patent Protection of Pharmaceutical
Products has shed some light on the meaning of the anti-discrimination provision of Article
27.1. In that decision, the panel addressed the meaning of the phrase "without discrimination"
as it is used in Article 27.1. The panel began by distinguishing the two different types of
discrimination: de jure and de facto discrimination." 6 De jure discrimination refers to
discrimination as a matter of law, based on explicit differences in treatment evident from the
terms of a law or regulation itself."7 De facto discrimination arises from discrimination as a
matter of fact that is not evident from reviewing the explicit terms of the law alone."' Thus,
discrimination based on field of technology that is evident in the law itself, is considered de
jure discrimination.
In considering the word "discrimination," the panel cautioned that
... [g]iven the very broad range of issues that might be involved in defining
the word 'discrimination' in Article 27.1 of the TRIPS Agreement, ... it
would be better to defer attempting to define that term at the outset, but
instead to determine which issues were raised by the record before the Panel,
and to define the concept of discrimination to the extent necessary to resolve
those issues.'' 9
The panel found no evidence of dejure discrimination on the face of the law at issue
in the dispute, but then it considered whether the effect of the law could nevertheless be
115 Panel Report, Canada Patent Protection of Pharmaceutical Products, WT/DSI 14/R (Mar. 17, 2000)
(adopted Apr. 7, 2000).
116 Id. at 7.94.
117 Id.
118 Id.
1 9 Id. at 7.98.
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considered defacto discrimination pursuant to TRIPS Article 27.1.12" The panel explained as
follows:
[D]e facto discrimination is a general term describing the legal conclusion that
an ostensibly neutral measure transgresses a non-discrimination norm because
its actual effect is to impose differentially disadvantageous consequences on
certain parties, and because those differential effects are found to be wrong or
unjustifiable. Two main issues figure in the application of that general concept
in most legal systems. One is the question of de facto discriminatory effect -
whether the actual effect of the measure is to impose differentially
disadvantageous consequences on certain parties. The other, related to the
justification for the disadvantageous effects, is the issue of purpose-not an
inquiry into the subjective purposes of the officials responsible for the
measure, but an inquiry into the objective characteristics of the measure from
which one can infer the existence or non-existence of discriminatory
objectives.' 2'
The panel found that the complaining party, the EC, had not presented sufficient
evidence to demonstrate that the challenged provision had either a "discriminatory effect
limited to patented pharmaceutical products" or a "discriminatory purpose."''2 2 Therefore, the
panel did not find defacto discrimination under Article 27.1 .123
By contrast, because the proposed amendments to India's patent law, which would
impact the fields of technology eligible for patent protection, would appear on the face of the
law itself, the analysis by a panel in this situation would be one of de jure, rather than de
facto, discrimination. In this case, the discrimination is directed at pharmaceutical substances
and micro-organisms.
120 Id. at 7 7.99-100.
... Id. at 7.101. (emphasis added).
122 Id. at 7 7.102-04.
123 Id. at 7.105.
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3. Article 27 authorizes specific exclusions from patent eligibility that do not exempt the
subject matter excluded in India's 'proposed exclusion'
Pursuant to TRIPS Article 27.1, the government must grant patents to all inventions in
all fields of technology if they are otherwise patentable, unless they are specifically excluded
by Articles 27.2 or 27.3.124 The only inventions that the government may exclude from patent
eligibility are inventions falling within the specific categories the TRIPS Agreement defines
in Articles 27.2 and 27.3.
Of importance is the fact that none of the exclusions specified in Articles 27.2 and
27.3 are required exclusions. Thus, consistent with TRIPS Article 1.1, WTO Members may
elect to not exclude from patentability the classes of inventions specified by these provisions.
As detailed herein, India cannot justify the exclusions for patent eligibility proposed
in its patent law by virtue of paragraphs two or three of TRIPS Article 27.
Since there is no indication that India would accompany its proposed exclusions from
patent eligibility with a ban on the sale of the inventions at issue, the exclusions
simply could not fit within the scope of the ordre public and morality exception of
TRIPS Article 27.2.
In particular, a requirement that a chemical compound constitutes a "new chemical
entity," in addition to being novel, involving an inventive step, and being industrially
applicable, would be inconsistent with the obligations of Article 27. The phrase "new
chemical entity" does not appear anywhere in Article 27.2 or 27.3. In fact, TRIPS
Article 39.3 reveals that the TRIPS drafters were fully aware of the concept of "new
chemical entity," but consciously chose not to use this phrase anywhere when
advising as to what types of inventions the government could deem ineligible for
patenting.
Similarly, the clear terms of Article 27.3 explain that Members do not have the
discretion to exclude "micro-organisms" from patentability (unless they were to fit
within a different exception). This section states, "Members may also exclude from
patentability ... plants and animals other than micro-organisms."
While the TRIPS Agreement does not use or define the term "new medical entity
(NME)", the term "new chemical entity (NCE)" appears for the first time in International
Intellectual Property agreements in the TRIPS Agreement of 1994, under Article 39.3:
Members, when requiring, as a condition of approving the marketing of
pharmaceutical or of agricultural chemical products which utilize new
chemical entities, the submission of undisclosed test or other data, the
124 See TRIPS Agreement, supra note 1, art. 27.1.
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origination of which involves a considerable effort, shall protect such data
against unfair commercial use. In addition, Members shall protect such data
against disclosure, except where necessary to protect the public or unless steps
are taken to ensure that the data are protected against unfair commercial use.125
According to the United States' Food and Drug Administration (FDA), a new
molecular entity (NME) or new chemical entity (NCE) means a drug that contains no active
moiety and has been approved by FDA under section 505(b) of the Federal Food, Drug, and
Cosmetic Act. 21
Other than Articles 27.2 and 27.3, no other provisions of the TRIPS Agreement
permit India to exclude certain inventions from eligibility for patent protection on a per se
basis. The "exceptions to rights conferred" in TRIPS Article 30 relate only to "the exclusive
rights conferred by a patent," and not to the issues of patentability covered by TRIPS Article
27. Article 30 provides that "[m]embers may provide limited exceptions to the exclusive rights
conferred by a patent, provided that such exceptions do not unreasonably conflict with a normal
exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner,
taking account of the legitimate interests of third parties.' ' 27 Nor do the provisions in TRIPS Article
3 1, related to "Other Use without Authorization of the Right Holder," involve the issue of
eligibility for patent protection. 128 Similarly, the General Council approved a pending
amendment to the TRIPS Agreement, on December 6, 2005, which does not relate to patent
eligibility, but instead to the use of patent rights. 129 Finally, the "principles" listed in TRIPS
Article 8.1, related to protecting public health and nutrition and promoting the public interest,
allow only for measures that "are consistent with the provisions of this Agreement",
including Article 27.130
125 See TRIPS Agreement, supra note 1, art. 39.3.
12' Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355 (1938).
127 See TRIPS Agreement, supra note 1, art. 30.
121 See TRIPS Agreement, supra note 1, art. 31 ("other use" refers to use other than that allowed under Article
30).
... See Amendment of the TRIPS Agreement, WT/L/641 (Decision of Dec. 6, 2005), available at
http://www.wto.org/english/tratop_e/trips_e/wt164 l-e.htm.
131 See TRIPS Agreement, supra note 1, arts. 8.1 & 27.
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a. Article 27.2 authorizes exclusions from patent eligibility only if necessary to
protect ordre public and morality
TRIPS Article 27.2 permits WTO Members to exclude inventions from patent
eligibility where "the prevention within their territory of the commercial exploitation of
which is necessary to protect ordre public or morality, including to protect human, animal or
plant life or health or to avoid serious prejudice to the environment, provided that such
exclusion is not made merely because the exploitation is prohibited by their law." In other
words, if a WTO Member prohibits the commercial exploitation of a particular invention
because doing so "is necessary" to protect ordre public or morality, he or she may also elect
to refuse to grant patents on such inventions, even though those inventions might be novel,
involve an inventive step and be capable of industrial application.
Thus, a WTO Member may not elect to permit general sale, supply or use of the
invention, but then refuse to grant patents on that product under the justification of Article
27.2. Instead, Article 27.2 authorizes a WTO Member to exclude inventions from patent
eligibility in order to prevent commercial exploitation, which would endanger ordre public'3'
or morality' 13 2. By contrast, the negotiating history reveals that negotiators presented text
(Brussels Draft) to the Ministerial Conference in Brussels in December 1990 that included a
broader exception, which allowed parties to exclude from patentability inventions that "the
prevention within their territory of the publication or any exploitation of which is necessary
to protect public morality or order . . .""' The fact that the negotiators chose to delete the
reference to "publication" and focus instead solely on commercial exploitation confirms the
understanding that Article 27.2 requires consideration of the effect of commercial
exploitation of an invention on morality and ordre public, not the effect of the granting and
publishing of a patent itself.
13' A more accurate meaning for this term would be "public policy," which concerns the public law principles
from which one cannot derogate without endangering the institutions of a given society. See DANIEL
GERVAIS, THE TRIPS AGREEMENT: DRAFTING HISTORY AND ANALYSIS 222 (Sweet & Maxwell) (2d ed.
2003).
... This concept is different from the concept of ordre public as it depends mostly on the culture of a given
country or region. It appears to correspond to the French concept of "bonnes moeurs". See GERVAIS, supra
note 13 1, at 223.
133 Draft Final Act Embodying the Results of the Uruguay Round of Multilateral Negotiations, TNC/W/35
Rev. 1 (Dec. 3, 1990), reprinted in GERVAIS. supra note 131. at 218.
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With respect to the proposed amendments to India's patent law, to the extent that the
subject matter that these amendments would exclude from patentability (i.e., micro-
organisms and certain pharmaceuticals) could continue to be marketed in India after passage
of the amendment (which appears to be the case), such an amendment could not be justified
by TRIPS Article 27.2.
The objective nature of the phrase "is necessary to protect . . ." in TRIPS Article 27.2
is important to note. This objective character is highlighted by relevant context, via
comparison of this provision with the formulation of the security exception in TRIPS Article
73(b). TRIPS Article 73(b) provides that "[n]othing in this Agreement shall be construed: ...
to prevent a Member from taking any action which it considers necessary for the protection
of its essential security interests.""'3 Thus, the difference between "is necessary" in Article
27.2, on the one hand, and "which [a Member] considers necessary" in Article 73(b), on the
other, emphasizes that a panel must consider what is and is not necessary for morality and
ordre public from an objective perspective.
Article 27.2 also clarifies that a Member may not exclude an invention from patent
eligibility simply because a national law regulates or prohibits its exploitation, but that
instead the Member must objectively justify the exclusion based on necessity to protect
morality or ordre public. This is consistent with Article 4quater of the Paris Convention,
which provides that,
[t]he grant of a patent shall not be refused and a patent shall not be invalidated
on the ground that the sale of the patented product or of a product obtained by
means of a patented process is subject to restrictions or limitations resulting
from the domestic law. 135
Dispute Settlement Panels and the WTO Appellate Body have provided guidance on
the meaning of exceptions similar to TRIPS Article 27.2 that appear in Article XX of the
General Agreement on Tariffs and Trade 1994 ("GATT 1994").13' A panel that analyzes
134 See TRIPS Agreement, supra note 1, art. 73(b) (emphasis added).
135 See Paris Convention, supra note 59, art. 4quater.
13' The General Agreement on Tariffs and Trade, 1867 U.N.T.S. 190, 33 I.L.M. 1125, 1154 (1994) [hereinafter
GATT], available at http://www.wto.org/english/docs e/legal e/gatt47 e.pdf.
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TRIPS Article 27.2 would likely refer to these earlier decisions for guidance. Specifically,
Article XX provides a general exception to GATT obligations, allowing Members to adopt or
enforce measures that, among other reasons, are "(a) necessary to protect public morals," or
"(b) necessary to protect human, animal or plant life or health." The panel in European
Communities Measures Affecting Asbestos and Asbestos-Containing Products, following
the practice of previous panels, found that a Member invoking Article XX (b) must prove:
(a) That the policy in respect of the measures for which Article XX is invoked
falls within the range of policies designed to protect human life or health; and,
(b) The inconsistent measures for which the exception is invoked are necessary to
fulfill the policy objective.'37
Panels have found a measure is "necessary" in cases where "there were no alternative
measure consistent with the General Agreement, or less inconsistent with it, which [the
Member] could reasonably be expected to employ to achieve its health policy objective."'38
Determining whether or not an alternative measure is reasonably available "must be assessed
in light of the economic and administrative realities facing the Member concerned." 3' Thus,
if a class of inventions may present a threat to public health, and appropriate regulatory
measures are reasonably available to resolve those concerns, a prohibition on commercial
exploitation would not be "necessary" under Article 27.2.
Since no indication exists that India is contemplating a ban on commercial
exploitation of pharmaceutical substances or micro-organisms to coincide with the proposed
exclusions on patentability, no need exists for a panel to even consider the justification for
such exclusions. In other words, if India does not prevent within its territory "the commercial
exploitation" of this subject matter, then its exclusions simply would not fall within the scope
of Article 27.2.
... Panel Report, European Communities Measures Affecting Asbestos and Asbestos-Containing Products,
8.169, WT/DS 135/R (Sep. 18, 2000) (adopted as modified by the Appellate Body Apr. 5, 2001).
138 Id. at 8.172 (quoting GATT Panel Report, Thailand Restrictions on Importation of and Internal Taxes
on Cigarettes, 75 BISD 37S/200.).
139 Id. at 8.208.
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b. Article 2 7.3(a) authorizes exclusions for a limited set of method inventions
In TRIPS Article 27.3, the exception for certain "methods"'40 does not cover India's
proposed exclusions from patent eligibility for "micro-organisms" and certain pharmaceutical
substances. Specifically, Article 27.3(a) provides that WTO Members may exclude certain
methods from patent eligibility, notwithstanding whether those methods meet the
requirements of being novel, involving an inventive step, and being industrially applicable.
Article 27.3(a) provides that "Members may also exclude from patentability: (a) diagnostic,
therapeutic and surgical methods for the treatment of humans or animals."''
Initially, one should recognize the importance in the fact that the scope of Article
27.3(a) is limited to inventions which are diagnostic, or therapeutic and surgical methods,
where the ordinary meaning of "method" is "[a] mode of procedure; a (defined or systematic)
way of doing a thing."'42 Such method must be for the "treatment of humans or animals"
before it is subject to the Article 27.3(a) exception.'43 By contrast, compounds, compositions
and machines that are used in diagnosis, therapy, or surgery involving humans or animals are
not excluded under the authority of Article 27.3(a), as these inventions are not "method"
inventions."'
As noted above, while Article 27.3(a) allows WTO Members to exclude methods used
for the surgical, diagnostic or therapeutic treatment of humans or animals from patent
'1 See TRIPS Agreement, supra note 1, art. 27.3 (provides that "[m]embers may also exclude from
patentability: (a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals; (b)
plants and animals other than micro-organisms, . ) (emphasis added).
'4' TRIPS Agreement, supra note 1, art. 27.3(a) (emphasis added).
1 THE NEW SHORTER OXFORD ENGLISH DICTIONARY 1752 (Lesley Brown ed., 1993).
.. Historically, many countries excluded therapeutic, surgical and diagnostic methods from patentability prior
to entry into force of the TRIPS Agreement, and thus they advocated for the inclusion of the exception now
included in TRIPS Agreement. See TRIPS Agreement. supra note 1. art. 27.3(a). The EPC, for example,
excluded such methods based on the reasoning that there was no industrial applicability (or utility) for such
creations. See EPC, supra note 29, art. 52(4). In general, most of these exclusions focused on methods that
were actually practiced on the human or animal body, thus reflecting the reference to surgical, diagnostic or
therapeutic methods.
14 See, e.g., EPC, supra note 29, art. 52(4) (clarifying that exclusion for methods does not apply to "substances
or compositions", but strictly to the method itself). Article 52(4) states as follows: "Methods for treatment
of the human or animal body by surgery or therapy and diagnostic methods practised on the human or
animal body shall not be regarded as inventions which are susceptible of industrial application within the
meaning of paragraph 1. This provision shall not apply to products, in particular substances or
compositions, for use in any of these methods."
8 Chi.-Kent J. Intell. Prop. 69
Copyright © 2008, Chicago-Kent Journal of Intellectual Property
protection it does not oblige its Members to do so. A Member could, for example, limit the
exclusions to only some (or none) of the classes of methods Article 27.3(a) references.
Of importance to remember is that Article 27.1 of the TRIPS Agreement obliges
WTO Members to grant patents for both products and processes.4  Therefore, new uses of
known products are eligible for patent protection. In particular, the narrow scope of the
Article 27.3(a) exception does not exclude methods for utilizing a newly discovered property
of a compound or composition for use in preparation of a medicament. A Member must
grant a patent to these methods, provided the method is novel, involves an inventive step and
is industrially applicable. 146 The exception in Article 27.3(a) does not cover such a method
because it is not strictly a "diagnostic, therapeutic, [or] surgical" method for treatment. This
interpretation is consistent with the practice of most countries that follow the EPC model.
The EPC model uses "Swiss claims" through which the innovative development of using a
previously known therapeutic compound or agent can be patented (e.g., through protection in
the form of use of the compound to prepare a medicament for the treatment of a particular
disease).'47 In such cases, the claim is drafted as a method of using the compound or agent to
produce a medicine for a new treatment modality, rather than a method for direct treatment of
humans or animals.
1-5 See TRIPS Agreement, supra note 1, art. 27.1(provides that "[s]ubject to the provisions of paragraphs 2 and
3, patents shall be available for any inventions, whether products or processes, in all fields of
technology...") (emphasis added).
146 See TRIPS Agreement, supra note 1, art. 27.1(provides that "... patents shall be available for any
inventions, whether products or processes, in all fields of technology, provided that they are new, involve an
inventive step and are capable of industrial application....") (emphasis added).
... See EPO Guidelines, supra note 42 at Pt. C, Ch. IV, § 4.2 ("A claim in the form 'Use of a substance or
composition X for the manufacture of a medicament for therapeutic application Z' is allowable for either a
first or 'subsequent' (second or further) such application (*second medical use-type of claim or 'Swiss-
type' claim), if this application is new and inventive .... ). In 1984, the Enlarged Board of Appeal
("EBA") of the European Patent Organization received seven cases dealing with the issue of patentability of
a so-called "second medical indication." See Case G 5/83 at 7, 9, O.J. 3/1985, 64. The EBA
acknowledged the established practice in the Swiss patent system of permitting "second (and subsequent)
medical indications by means of a claim directed to the use of a substance or composition for the
manufacture of a medicament for a specified (new) therapeutic application." Id. at 19. The EBA further
reasoned that, in its interpretation of the concept of the "state of the art" as defined in Article 54 of the EPC,
there was no intention to exclude second (and subsequent) medical indications from patentability "other
than by a purpose-limited product claim." Id. at 22.
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c. Article 2 7.3(b) authorizes exclusions for a sub-set ofplants, animals, plant
varieties, and biological processes
Article 27.3(b) effectively addresses three distinct issues. First, it confirms that WTO
Members must grant patents on micro-organisms and other living organisms other than plants
or animals, provided the organism is novel, involves an inventive step, and is industrially
applicable.'48 Second, it authorizes, but does not require, WTO Members to exclude from
patent eligibility plant and animal inventions, regardless of whether those inventions are
novel, involve an inventive step, and are industrially applicable. 4 9 Third, it imposes an
obligation on certain WTO Members (i.e., those that exclude plants from patent eligibility) to
grant sui generis protection for plant varieties.""
As expressed in the TRIPS Agreement, Article 27.3(b) provides that Members may
exclude from patentability:
plants and animals other than micro-organisms, and essentially biological processes
for the production of plants or animals other than non-biological and microbiological
processes. However, Members shall provide for the protection of plant varieties either
by patents or by an effective sui generis system or by any combination thereof. The
provisions of this subparagraph shall be reviewed four years after the date of entry
into force of the WTO Agreement. 151
To clarify what is and is not excluded by this provision, one must consider the
ordinary meaning of three key terms: 1) plants, 2) animals, and 3) micro-organisms. As
clearly illustrated in the text of Article 27.3(b), Members cannot exclude micro-organisms
from patent eligibility. The ordinary meaning of micro-organism is "an organism too small to
be seen except with the aid of a microscope, as a bacterium or virus."'5 2 Historically, within
this group, scientists have classified organisms such as self-propagating individual cell lines
of animal (e.g., human), plant, fungi, algae, protozoa, bacteria, or viral origin.'53 The
International Patent Classification (IPC) is maintained by the World Intellectual Property
141 See TRIPS Agreement, supra note 1, art. 27.3(b).
149 Id.
150 Id.
151 Id. (emphasis added).
'-5 1 THE NEW SHORTER OXFORD ENGLISH DICTIONARY 1766 (Lesley Brown ed., Clarendon Press) (1993).
153 See J. COOMBS, MACMILLAN DICTIONARY OF BIOTECHNOLOGY1 88 (1986) ("microorganism" refers to an
organism that can belong to one of five classes or organisms: bacteria, fungi. algae. protozoa or viruses).
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Organization (WIPO), and used by the industrial property offices of more than 100 countries,
four regional offices, and the International Bureau of WIPO.'54 The IPC provides guidance to
a WTO panel as to the meaning of "micro-organisms" as relevant state practice (both before
and after the TRIPS Agreement).'55 Specifically, it categorizes micro-organisms under
Category C12, and states that "viruses, undifferentiated human, animal or plant cells,
protozoa, tissues and unicellular algae are considered as micro-organisms."'56 Further, the
IPC distinguishes micro-organisms as being in an entirely separate classification (C12) from
plants (AO1H) and animals (AO1K), confirming that the WTO panel should consider them as
three distinct categories of organisms. 157
The ordinary meaning of "plant" is a "living organism other than an animal, typically
fixed to a substrate, able to subsist wholly on inorganic substances, and moving chiefly by
growth"'' 58 and "a living organism (such as a tree, grass, or fern) that absorbs water and
inorganic substances through its roots and makes nutrients in its leaves by photosynthesis."'' 59
Finally, the term "animal" refers to a "living organism having sensation and voluntary
motion, without rigid cell walls, and dependent on organic substances for food."'6 ° In
addition, "a living organism which feeds on organic matter, has specialized sense organs and
nervous system, and is able to move about and to respond rapidly to stimuli."'' Such
definitions illustrate that a Member cannot consider a single-celled organism to be a "plant"
or an "animal," and consequently cannot exclude it from patentability without violating the
1 The International Patent Classification [hereinafter IPC] is based on the Strasbourg Agreement Concerning
the International Patent Classification, which was concluded in 1971 and entered into force in 1975. See
About the International Patent Classification, http://www, wipo.intlclassificationslipclenlgenerall.
¢' The sixth edition of the IPC, which was in force prior to entry into force of the TRIPS Agreement, is
available at http ://www"w.ipo.intlclassificationslfulltextlnew ipclipc6/e index. htm.
International Patent Classification, 8th Edition, available at
http: //www. wipo.intlclassificationslipeipc8/?lang en.
151 Id. According to the International Patent Classification A01H includes new plants or processes for
obtaining them; plant reproduction by tissue culture techniques, AO1K includes animal husbandry; care of
birds, fishes, insects; fishing; rearing or breeding animals, not otherwise provided for; new breeds of
animals and C12 includes biochemistry; beer; spirits; wine; vinegar; microbiology; enzymology; mutation
or genetic engineering.
'5' 2 THE NEW SHORTER OXFORD ENGLISH DICTIONARY 2237 (Lesley Brown ed., 1993).
'5 THE OXFORD COMPACT ENGLISH DICTIONARY 864 (2d ed. rev. 2003).
I0 1 THE NEW SHORTER OXFORD ENGLISH DICTIONARY 80 (Lesley Brown ed., 1993).
161 THE OXFORD COMPACT ENGLISH DICTIONARY 36 (2d ed. rev. 2003).
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TRIPS Agreement. Moreover, single-celled organisms that are microscopic would fall within
the definition of micro-organism.
Indeed, the structure of TRIPS Article 27.3(b), within the context of the other
paragraphs of Article 27, obligates Members to grant patents on living organisms, other than
any organism that falls within the scope of the ordinary meaning of the terms plants or
animals, including, but not limited to, an obligation to make micro-organisms eligible for
patent protection. This obligation stems from two aspects of the text. First, Article 27.3(b) is
conditional on the overarching obligations of Article 27.1 to grant patents on any invention in
allfields of technology not explicitly excluded by Articles 27.2 and 27.3, and that is novel,
involves an inventive step, and is industrially applicable. 2 Thus, a Member may exclude
from patentability only those inventions that are explicitly identified in Article 27.3(b) (i.e.,
plants and animals). Any other living organism inventions must remain eligible for a patent,
including, in particular, micro-organisms, unless they are subject to another exception.
Second, the explicit exemption of "micro-organisms" from the authority to exclude plant and
animal inventions found in Article 27.3(b) reinforces the fact that all organisms other than
plants and animals must remain eligible for a patent. 163
This interpretation is confirmed by the negotiating history of the provision. The final
text of Article 27.3(b) provides a much more narrow authority to exclude living organism
inventions than certain negotiating parties to the Uruguay Round had originally proposed.'64
Notably, in the draft of July 23, 1990, prior to the Brussels draft, a number of developing
countries sought a mandatory exclusion of all living organisms from patentability (i.e., one
that would require all WTO Members to refuse patents on living organisms). 65 Others sought
162 See TRIPS Agreement, supra note 1, art. 27.
163 As early as 1980, the U.S. Supreme Court held that a live, human-made micro-organism is patentable
subject matter under U.S. patent law. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
... See Draft Final Act Embodying the Results of the Uruguay Round of Multilateral Negotiations, (b)B,
(c)B TNC/W/35 (Rev.1 of 3, Dec. 1990) (emphasis added) reprinted in GERVAIS, supra note 131, at 218.
The proposed bracketed text in paragraph 3(b)B would have allowed Members to exclude from
patentability "Plants and animals, including microorganisms. and parts thereof and processes for their
production. As regarding biotechnology inventions, further limitations should be allowed under national
law." Id. Moreover, the proposed bracketed text in paragraph 3(c)B would have allowed parties to exclude
from patentability "[c]ertain products and processes for the manufacture of those products. on grounds of
public interest, national security, public health or nutrition, including food, chemical and pharmaceutical
products and process for the manufacture of pharmaceutical products." ld
65 See The Anell Draft, Report to the General Negotiating Group (GNG) on the status of work in the TRIPS
Negotiating Group, July 23, 1990 (W/76), reprinted in GERVAIS, supra note 131, at 219.
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a more comprehensive and unconditional authority to exclude living organisms (including
micro-organisms) from patent eligibility.' Ultimately, negotiators did not adopt these
proposals for broad exceptions.
Consequently, the negotiating history confirms that lawmakers considered the
proposed amendments to India's patent law to exclude micro-organisms as a possibility in the
early stages of negotiations of the TRIPS Agreement, but squarely rejected them in the final
agreement.
Finally, Article 27.3(b) impacts the broad requirement for patentability of Article 27.1
in several other ways. It provides Members the discretion to exclude from patentability
"essentially biological processes for the production of plants or animals other than the non-
biological and microbiological processes."'167 Thus, the possibility of excluding essentially
biological processes does not extend to non-biological or microbiological processes.'
Article 27.3(b) also requires that plant varieties be protected by patents, a sui generis system,
or both. Some Members suggested a sui generis system that was a UPOV-type system.'69
WTO Members are not mandated to adopt this precise system of protection, but are free to
develop another type of protection for their plant varieties, as long as it is an effective one.
4. The context, object and purpose, and negotiating history of the TRIPS Agreement
confirms that pharmaceutical substances must be eligible for patent protection
Other provisions of the TRIPS Agreement provide relevant context that reinforces the
conclusion that India's proposed amendments would violate the Agreement. Specifically,
TRIPS Articles 70.8 and 70.9 provide a system for preserving future patent rights and for
166 Id.
17 TRIPS Agreement, supra note 1, art. 27.3(b) (emphasis added). Directive 98/44/EC of the European
Parliament and of the Council of July 6, 1998 on the legal protection of biological inventions [hereinafter
EC Biotech Directive] explains that *[a] process for the production of plants or animals is essentially
biological if it consists entirely of natural phenomena such as crossing or selection." EC Biotech Directive,
art. 2. As per the European Patent Office, the concept of "essentially biological process" is also related to
the degree of technical intervention made on the biological process. See EPO Guidelines. supra note 42, at
Pt. C, Ch. IV, § 3.4.2.
I6, The EC Biotech Directive defines "microbiological process" as "any process involving or performed upon
or resulting in microbiological material." See EC Biotech Directive, art. 2.
... UPOV is the French abbreviation for the "International Union for the Protection of New Varieties of
Plants." It was adopted in Paris in 1961. See www.upov.int.
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granting current exclusive marketing rights in pharmaceutical products in certain Members
who did not extend patent protection to pharmaceutical products as of the date the TRIPS
Agreement went into effect. 7 ' India was one such country. The so-called "mailbox" and
"exclusive marketing rights" provisions would have been unnecessary if Members had the
discretion under Article 27.1 to simply exclude pharmaceutical product inventions from
patent eligibility. Also important to note is that these transitional measures contain no
limitations related to the "significance" of the particular attributes of the pharmaceutical
product in question.'7' Thus, if a pharmaceutical product is a particular salt or polymorph of a
previously known active ingredient, a Member must grant it protection under Articles 70.8
and 70.9. Logically, that product must be eligible for a patent.
An interpretation of TRIPS Article 27.1 that would authorize per se exclusions for
certain types of pharmaceutical product inventions would also plainly conflict with what was
the accepted outcome of the intellectual property negotiations of the Uruguay Round. When
the Uruguay Round of negotiations began, approximately 50 countries did not grant patents
on pharmaceutical products. 7 2 Many bitterly fought over the concession that these countries
made to grant pharmaceutical product patents. At the conclusion of negotiations on the
TRIPS Agreement, these countries, led by India, advocated for the inclusion of TRIPS Article
65.4, which provided an additional implementation period for certain developing countries to
make pharmaceutical products, among other inventions, eligible for patent protection.'73
Dozens of these countries have subsequently implemented pharmaceutical product protection
standards without any per se exclusions or other conditions.'74 By contrast, WTO Members
have granted an extension to underdeveloped countries such that they are not obligated to
170 See TRIPS Agreement, supra note 1, arts. 70.8 & 70.9.
... See TRIPS Agreement, supra note 1, art. 70 (specifies that "this Agreement gives rise to obligations in
respect of all subject matter existing at the date of application of this Agreement for the Member in
question, and which is protected in that Member on the said date, or which meets or comes subsequently to
meet the criteria for protection under the terms of this Agreement.") (emphasis added).
72 See Memorandum of the International Bureau of WIPO on Exclusions from Patent Protection
HL/CM/INF/1, available at www.wipo.int. (accessed on Jan. 14, 2008). This Memorandum was elaborated
in order to present information on what fields of technology used to be excluded from patent protection
under the patent laws of every country in the world.
173 See TRIPS Agreement, supra note 1, art. 65.4 (extending the deadline to Jan. 1, 2005).
4 E.g., Brazil and India amended their patent laws to start granting patents on medicines in 1996 and 2005,
respectively to comply with their international obligations under the Agreement on Trade Related Aspects
of Intellectual Property Rights.
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implement the patent or undisclosed information sections of the TRIPS Agreement, with
respect to pharmaceutical products, until January 1, 2016.'7 India is not considered an
underdeveloped country, and thus not subject to this exclusion.
III.INDIA'S NATIONAL INTEREST AND OPTIONS
India's socio-economic context, where millions are unable to access the public
healthcare system, requires that India balance the right of access to affordable medicines with
patent rights. The main justifications of the proponents'76 of proposed exclusion are that an
exclusion would prevent a phenomenon commonly known as 'ever-greening" 77 of
pharmaceutical products, and that it would further public health aims by restricting the extent
of patentability of pharmaceutical inventions, so as to keep the prices of drugs to pre-1995
levels. They argue that the objective and principles of the TRIPS Agreement mentioned in
Articles 7 and 8, in conjunction with Paragraph 4 of Doha Declaration provide sufficient
flexibility to enable this objective.'78
Article 7 states:
The protection and enforcement of intellectual property rights should
contribute to the promotion of technological innovation and to the transfer and
dissemination of technology to the mutual advantage of producers and users
of technological knowledge and in a manner conducive to social and
'79economic welfare, and to a balance of rights and obligations .
Article 8 states:
1. Members may, in formulating or amending their national laws and
regulations, adopt measures necessary to protect public health and nutrition
and to promote the public interest in sectors of vital importance to their socio-
75 See Doha Declaration, supra note 92, para. 7.
176 K. M. Gopakumar, Mashelkar Committee Report: A Critique, Center for Trade and Development
(CENTAD), available at http://www.centad.org/focus 33.asp (accessed on Jan. 14, 2008).
'Ever-greening' is a term used to refer loosely to inappropriate extensions in the period of patent exclusivity
for a pharmaceutical product. See Basheer. supra note 14, at 39.
178 See TRIPS Agreement, supra note 1, arts. 7 & 8 and Doha Declaration, supra note 92, para 4.
"9 See TRIPS Agreement, supra note 1,art. 7 (emphasis added).
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economic and technological development, provided that such measures are
consistent with the provisions of this Agreement.
2. Appropriate measures, provided that they are consistent with the
provisions of this Agreement, may be needed to prevent the abuse of
intellectual property rights by right holders or the resort to practices which
unreasonably restrain trade or adversely affect the international transfer of
technology. 180
Paragraph 4 of Doha Declaration states:
We agree that the TRIPS Agreement does not and should not prevent
members from taking measures to protect public health. Accordingly, while
reiterating our commitment to the TRIPS Agreement, we affirm that the
Agreement can and should be interpreted and implemented in a manner
supportive of WTO members' right to protect public health and, in particular,
to promote access to medicines for all .181
While Article 7 and 8 are general provisions that certainly provide flexibility to the
member States to frame laws balancing the availability of patent rights with their socio-
economic goals, many doubts exist regarding whether these Articles provide the freedom to
the member States to interpret the TRIPS Agreement in so wide a manner as to bring about
renegotiation of basic balance of TRIPS Agreement. 182
Moreover, since the R&D capabilities of local industry have not yet reached that
critical level where it can engage in discovery or development of new chemical entities, the
incentives for sequential pharmaceutical developments are as necessary as or even more
necessary than the creation of NCEs or NMEs. At present, the local pharmaceutical industry
directs most of the R&D activities towards minor modifications of drugs that foreign
countries have developed. Therefore, patent protection for incremental innovation can be of
immense value to the industry as it caters to the local requirements of India such as NDDS.
NDDS are formulations that are developed specifically suited to the local environmental
'o See TRIPS Agreement, supra note 1,art. 8 (emphasis added).
181 See Doha Declaration, supra note 92, para. 4 (emphasis added).
182 See Basheer, supra note 14, at 30-34.
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conditions. For example, Ranbaxy has licensed its NDDS on ciprofloxacin to Bayer AG,
which enabled a patient to take medicine just once a day."3
India can tackle the issue of 'ever-greening' by not granting secondary patents on the
basis of trivial and insignificant changes to the original pharmaceutical product and by
ensuring that generic versions of the original drug can be marketed after patent protection has
expired. Ensuring that regulatory approval for the original product is retained as a reference
product for generic copies can aid the issue of 'ever-greening'.1 4
Article 27 states that "patents shall be available for any inventions ... provided that
they are new, involve an inventive step and are capable of industrial application.""' Hence,
this provision certainly provides some flexibility to the member States to define the
patentability criteria in a manner that suit their national interest. However, the word
'invention' has to be vested with some basic meaning. At the very least, this word must
denote something of "technical" import. If the member States were free to interpret according
to their whims and fancy, we could end up with a situation where a member State may argue
that it did not need to grant patents at all, since its unique lexicon suggests that nothing ever
amounts to an "invention" under Article 27. In short, this freedom of interpretation would
render the term "invention" redundant and such a result would derogate the basic tenet of
treaty interpretation well-accepted under international law: one cannot read a treaty term in a
manner as to render it redundant.
The Indian government has, in fact, utilized this provision and has made wide-ranging
provisions in the Patent (Amendment) Act, 2005 to prevent the grant of patents to trivial and
insignificant pharmaceutical inventions. For example,
'New Invention': The Patent (Amendments) Act, 2005 defines the term 'New
Invention' as
[A]ny invention or technology which has not been anticipated by publication
in any documeni or used in the county or elsewhere in the world before the
.. See Padmashree Ghel Sampath, UNITED NATIONS UNIVERSITY-INSTITUTE FOR NEW TECHNOLOGIES (UNU-
INTECH), Economic Aspects ofAccess to Medicines after 2005: Product Patent Protection and Emerging
Firm Strategies in the Indian Pharmaceutical Industry. (2005), available at
http://www.who.int/i ntellectualproperty/studies/PadmashreeSampathFinal.pdf.
184 See Basheer, supra note 14, at 40.
185 See TRIPS Agreement, supra note 1,art. 27.1 (emphasis added).
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date of filing of a patent application with complete specification, i.e. the
subject matter has not fallen in public domain or that it does not form part of
the state of the art ,. ,16
Since the 'novelty' standard under the Act is 'absolute' and not 'relative,' fewer
pharmaceutical inventions would clear the 'novelty' test.
'Inventive step': The Patent (Amendments) Act, 2005 makes a critical change to the
earlier 'non-obviousness' or 'Inventive step' test. The definition now reads,
'inventive step' means a feature of an invention that involves technical advance as compared
to the existing knowledge or having economic significance or both and that makes the
invention not obvious to the person skilled in the art. '
Thus, while the basic yardstick, i.e. 'not obvious to the person skilled in the art'
remains the same, the requirement of 'technical advance' or have an 'economic significance'
has made the definition of 'inventive step' susceptible to being interpreted in a manner that
renders it more onerous to satisfv. Hence, a proper application of this 'inventive step' or
'non-obviousness' will render non-meritorious pharmaceutical inventions non-patentable.
The 'New Use' Exclusion: Section 3(d) of the Patent Act, 1970 excluded a "new use for
a known substance" from the ambit of 'invention.' The 2005 Act has expanded on this
exception by providing that "the mere discovery of a new form of a known substance,
which does not result in the enhancement of the known efficacy of that substance" would
not be patentable.' This Act then states (via an explanation to the section) that salts,
esters, ethers, polymorphs, metabolites, etc. shall be considered as the same substance
unless they "differ significantly in properties with regard to efficacy ."189
If the patent office construes the term of 'efficacy' strictly, this term could be very
useful in curbing new grants of patents for incremental pharmaceutical innovations. On the
other hand, if the patent office interprets the term 'efficacy' liberally by the patent office, a
"' See The Patent (Amendment) Act § 2(1)(1), No. 15 of 2005; India Code (2005).
.. See Id. at § 2(1)(ja), No. 15 of 2005; India Code (2005).
188 See Basheer supra note 2, at 23.
189 Id.
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good number of formulations may qualify as new substances, upon showing an increased
efficacy.
Patent eligibility and subject matter exclusions: Apart from 'new use' exclusion,
the Patent Act has several patent eligibility or subject matter exclusions such as the 'method
of treatment' exception 9 and the 'product of nature' exclusion. The patent office could use
these exclusions to limit the range of patentable pharmaceutical inventions.
Thus, the provisions are in place in the statute books and an effective application of
the above patentability criteria in Patent Offices and the Courts would ensure that trivial and
insignificant changes do not merit patent protection.
As explained earlier, if a Member denies a patent to a micro-organism on the ground
of ordre public or immorality, one has to also forego the commercialization of the said micro-
organism. Prohibiting all forms of 'micro-organisms' is not feasible; especially when
biotechnology offers immense opportunity and potential. Therefore, India may not provide
for a per se exclusion of 'micro-organism' from patentability, and instead use the flexibilities
the TRIPS agreement provides in order to limit the scope of protection for micro-organisms.
The various options available to India in this regard are presented below:
Definition of 'Micro-organism': TRIPS does not define the 'micro-organism.' The
dictionary/scientific definition of 'micro-organism' is not conclusive, since there are several
such definitions, embodying different approaches. 1' Hence, India should use the ambiguity
associated with defining the term 'micro-organism' to its advantage and define 'micro-
organism' in precise terms that suit its socio-economic interests.
The 'discovery exception': Although the 'discovery exception is not explicitly
mentioned in TRIPS, most patent regime exclude mere 'discoveries' or 'law of nature' from
patentability. 92 Apparently, India's position is also that the discoveries are not patentable.
However, explicit use of the word 'discovery,' 'mere discovery,' and 'invention' in Section
'9 See The Patent (Amendment) Act § 3(i), No. 15 of 2005; India Code (2005). (excludes from patentability,
'any process for the medicinal, surgical. curative, prophylactic, diagnostic. therapeutic or other treatment of
human beings .... ').
'9' See Basheer, supra note 14, at 52.
192 See The Patent (Amendment) Act § 3(c), No. 15 of 2005; India Code (2005) (excludes the -discovery of
any living thing or non-living substances occurring in nature.").
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three shows the intention of the legislature for these words to have different meaning and
their patentability to differ case by case. Hence, one may remove the ambiguity, if any, in the
word 'discovery' and strengthen the 'discovery' exception by stipulating that mere isolation
or purification of a micro-organism by known procedures will not render it patentable.
Rather, only truly 'invented' micro-organisms, such as genetically modified ones, would be
patentable.
'Patentability' criteria: Article 27 gives some leeway to the members' States to
define 'patentability' criteria in a manner that suits their specific national interests. They
could specifically use this flexibility to apply to patent applications claiming micro-
organisms. This use could be in the form of examination guidelines, which the patent office
would apply strictly to ensure that it only grants truly meritorious inventions patent
protection. Using a guideline-based approach rather than substantive law is a better approach
because a guideline-based approach has the advantage of flexibility and ease of amendment
in light of changing technologies and policy considerations. 193
The above discussion demonstrates that without accepting the 'proposed exclusions'
and amending the Patents (Amendment) Act, 2005, India can still effectively address its
public health concerns and the needs and aspiration of the pharmaceutical industry by
utilizing the freedom that the TRIPS Agreement and Doha Declaration leaves for the
members States. This use of TRIPS and the Doha Declaration would not only establish
India's standing in the WTO, but would also enhance its reputation as a safe trading partner.
CONCLUSION
The foregoing discussion clearly establishes that the Technical Expert Group rightly
recommended that (a) limiting the grant of patents for pharmaceutical substances to new
chemical entities or to new medical entities, and (b) excluding micro-organisms from patent
eligibility will be in contravention with India's obligation under the TRIPS Agreement. The
recommendation of the Expert Group is supported by the following aspects of the TRIPS
Agreement:
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In pursuance of Article 27 of the TRIPS Agreement, WTO Members must make
patents "available for any invention whether products or processes, in all fields of
technology, provided that they are new, involve an inventive step and are capable of
industrial application"." 4 These exclusions violate the clear and broad mandate of TRIPS
Article 27.1 by denying patents for inventions that satisfy the other criteria for patentability.
By denying patent protection solely on the grounds that the invention is a micro-
organism or certain type of pharmaceutical substance, India's amendments would also violate
the requirement in TRIPS Article 27.1 that "patents shall be available . . . without
discrimination as to ... the field of technology."
The specific discretion provided to Members in TRIPS Article 27.2 and 27.3 with
respect to subject matter that may be excluded from patentability does not cover India's
proposed exclusions. . Indeed, TRIPS Article 27.3 specifically provides that micro-
organisms, in particular, may not be excluded from patentability. No other provision of the
TRIPS Agreement justifies the inconsistency of India's proposed amendments with TRIPS
Article 27.
The above discussion sufficiently clarifies that the recommendations of the Technical
Expert Group on patent issues headed by Dr. RA Mashelkar were perfectly in consonance
with the India's international obligation under the TRIPS Agreement. The problem was that
the Expert Group did not provide any legal evidence in support of its recommendations. India
must reject the 'proposed exclusions' in order to avoid a successful challenge by WTO
Members under Article 27 of the TRIPS Agreement. No one can demonstrate that the TRIPS
Agreement allows Members to refuse to grant patents on pharmaceutical inventions or micro-
organisms that are new, involve an inventive step, and are capable of industrial application.
Pharmaceutical products, in particular, are chemical compounds. Unless a Member
prohibits any commercialization of a particular chemical compound for reasons, within the
meaning of TRIPS Article 27.2, of ordre public or morality, or to avoid serious prejudice to
the environment, that compound, as well as a pharmaceutical product incorporating that
chemical compound, must be eligible to be patented.' The reason is because chemical
194 See TRIPS Agreement, supra note 1, art. 27.1 (emphasis added).
195 See Basheer, supra note 14, at 58,59.
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compounds do not fall within any of the categories of subject matter that a Member may
exclude under Articles 27.2 and 27.3. Nor do micro-organisms fall within those categories.
Looking beyond its international legal obligations, India must also provide for
patentability of micro-organisms and pharmaceutical substances in order to create the proper
incentives to foster the future growth of its research-based pharmaceutical and biotechnology
industries. In this manner, rejection of the 'proposed exclusions' will be an important step
toward continuing the advancement not only of the economic welfare of the Indian
population through growing businesses, but also of the development of micro-organisms and
pharmaceutical substances that contribute to national and global health.
Besides, the TRIPS Agreement, as discussed above, leaves significant freedom for
members States to determine the 'patentability criteria' as per their socio-economic and
welfare needs. Applying a low threshold may facilitate the patenting of incremental
developments, which predominate in domestic industry in developing countries like India.
However, this tactic would unduly restrain competition and increase litigation costs in key
areas such as pharmaceuticals where extensive patenting of minor developments has become
normal practice.'96 Given the market disruption and costs low or non-inventive development
patents may cause, India as the World Bank suggested, may opt for high standards of
inventiveness thereby preventing routine discoveries from being patented.'97 In fact, the
Patent (Amendment) Act, 2005 has headed in this direction by introducing more rigorous
requirements for 'inventive step' and the expansive 'new use' exclusion.' 8 These higher
standards could certainly help in curbing new grants of patents for incremental
pharmaceutical innovations.
India should make every effort to prevent the grant of frivolous patents and 'ever-
greening.' The Indian Patent Office should formulate and implement detailed Guidelines for
examining the patent applications in the pharmaceutical sector in order to eliminate the
remotest possibility of granting frivolous patents. Similarly, India must formulate strict
standards and detailed Guidelines for examination of the patent applications involving micro-
organisms from the point of view of substantial human intervention and utility. Alternatively,
196 See, e.g., CARLOS CORREA, TRENDS IN DRUG PATENTING. CASE STUDIES (2001).
117 World Bank, Global Economic Prospects and the Developing Countries 143 (2001).
" See Basheer supra note 2. at 34.
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India could adopt related forms of IP in order to promote and reward minor innovations, such
as utility models.'99
The discussions in this article clearly establish that the Doha Declaration and flexible
provisions of the TRIPS Agreement give us adequate opportunity to frame law to protect our
national interest without amending the Patent Act, which would be contrary to the provisions
of the TRIPS Agreement.
199 Utility models protect the functional aspect of models and designs, generally in the mechanical field. See
Uma Suthersanen, Utility Models and Innovation in Developing Countries, UNCTAD-ICTSD Project on IPRs
and Sustainable Development. (2006) available at http://www.unctad.org/en/docs/iteipc20066 en.pdf. Though
novelty and inventiveness are required, the criteria for conferring protection are generally less strict than for
patents. Id. The term of protection also is shorter. Id. Utility models are concerned with the way in which a
particular configuration of an article works, unlike industrial designs, which are only concerned with its
ornamental aspect. Id.
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